Category: Side Effect: Bone Disease (osteonecrosis, osteomyelitis, drug-related fracture)
-
Plaintiffs Win the Latest Round in Long-Running Fosamax Femur Fracture Litigation
Federal Appeals Court Rejects Merck's Legal Defense of Federal Preemption in September 2024 (Posted by Tom Lamb at Drug Injury Watch) UPDATE: On June 16, 2025, the U.S. Supreme Court rejected Merck's petition for certiorari filed…
-
Fosamax Femur Fracture Federal Court MDL Lawsuits Are Dismissed For a Second Time in March 2022
In a Long-Awaited Opinion, Federal Court Judge Wolfson Rules in Favor of Merck on Federal Preemption Legal Issue (Posted by Tom Lamb at Drug Injury Watch) On March 23, 2022, the federal court product liability…
-
Injectafer: Hypophosphatemia Warning Added To Drug Label In February 2020 (Finally)
Severe Hypophosphatemia Can Lead To Various Serious And Sometimes Fatal Medical Complications (Posted by Tom Lamb at DrugInjuryWatch.com) A February 21, 2020 FDA email informed us about an Injectafer drug label change…
-
Merck Wants The US Supreme Court To Reverse A Federal Appeals Ruling In Fosamax – Femur Fractures Litigation
At Issue Is Whether Failure-To-Warn Claims By Plaintiffs Are Blocked By Federal Preemption Legal Doctrine, As Merck Contends (Posted by Tom Lamb at DrugInjuryWatch.com) UPDATE: U.S. Supreme Court Hearing For Fosamax Appeal…
-
Fosamax – Femur Fracture Lawsuits In Federal Court MDL: March 2017 Appellate Court Ruling Reinstates Lawsuits
Third Circuit Panel Reverses Earlier Dismissal Of Plaintiffs Cases By District Court Judge Pisano On Federal Preemption Grounds (Posted by Tom Lamb at DrugInjuryWatch.com) UPDATE: Supreme Court Agrees To Review Fosamax…
-
Fall 2016 Update On Fosamax Femur Fracture Lawsuits Is Not Much Different Than What Was Reported A Year Ago
Bottom Line Is That The Fate Of These Lawsuits Against Merck Is In The Hands Of The U.S. Court of Appeals For The Third Circuit (Posted by Tom Lamb at DrugInjuryWatch.com) UPDATE:…
-
Invokana, Invokamet, Farxiga, Xigduo: Warnings About Acute Kidney Injury Risk Are Increased On Revised Drug Labels For These Diabetes Medicines
Meanwhile Jardiance, Glyxambi, And Synjardy, Also In The SGLT2 Inhibitors Class Of Diabetes Drugs, May Help Slow Progression Of Kidney Disease In Patients At High Cardiovascular Risk (Posted by Tom Lamb at DrugInjuryWatch.com)…
-
Merck Provides First 2016 Update For Fosamax – Femur Fracture Products Liability Lawsuits
About 4,400 Cases Still Pending In Federal Court MDL As Well As New Jersey And California State Courts (Posted by Tom Lamb at DrugInjuryWatch.com) UPDATE: On March 22, 2017 the Third Circuit…
-
Lawyers For Plaintiffs And Drug Company Merck Make Their Arguments To Third Circuit Appeals Court In Fosamax – Femur Fracture Litigation
One Of The Legal Issues Is Whether Merck Could Have And Should Have Strengthened The Drug Label Warnings About This Apparent Side Effect, Or Not (Posted by Tom Lamb at DrugInjuryWatch.com) UPDATE:…
-
Diabetes Drug Invokana Gets Label Changes For New Warnings About Increased Risk Of Bone Fracture Risks
The FDA Is Investigating Whether Farxiga And Jardiance Are Also Associated With Higher Rates Of Bone Breaks (Posted by Tom Lamb at DrugInjuryWatch.com) ________________________________________________________________________________ UPDATE: “Health Canada Warns About Link Between DKA &…